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Abstract
Upregulation of cytokines and chemokines is a frequent finding in multiple myeloma (MM).
CCL3 (also known as MIP-1α) is a pro-inflammatory chemokine whose levels in the MM
microenvironment correlate with osteolytic lesions and tumor burden. CCL3 and its receptors,
CCR1 and CCR5, contribute to the development of bone disease in MM by supporting tumor
growth and regulating osteoclast (OC) differentiation. Here, we identify inhibition of osteoblast
(OB) function as an additional pathogenic mechanism in CCL3-induced bone disease. MM-
derived and exogenous CCL3 represses mineralization and osteocalcin production by primary
human bone marrow stromal cells and HS27A cells. Our results suggest that CCL3 effects on OBs
are mediated by ERK activation and subsequent downregulation of the osteogenic transcription
factor osterix. CCR1 inhibition reduced ERK phosphorylation and restored both osterix and
osteocalcin expression in the presence of CCL3. Finally, treating SCID-hu mice with a small
molecule CCR1 inhibitor suggests an upregulation of osteocalcin expression along with OC
downregulation. Our results show that CCL3, in addition to its known catabolic activity, reduces
bone formation by inhibiting OB function and therefore contributes to OB/OC uncoupling in MM.
Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research,
subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
Corresponding author: Prof. Noopur Raje, MD, POB 216, MGH Cancer Center, Massachusetts General Hospital, 55 Fruit Street,
Boston, MA, 02114, USA, nraje@partners.org, Phone: +1-617-726-0711, Fax: +1-617-724-6801.
DISCLOSURE OF CONFLICT OF INTEREST
The author NR is consultant for Celgene and Novartis, member of the advisory committee for Celgene and Amgen, and she received
research funding from Astra Zeneca and Acetylon. P.V. is an employee of Millennium Pharmaceuticals.
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
NIH Public Access
Author Manuscript
Leukemia. Author manuscript; available in PMC 2014 August 25.
Published in final edited form as:
Leukemia. 2011 July ; 25(7): 1174–1181. doi:10.1038/leu.2011.43.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tKeywords
Myeloma; CCL3; Osteoblast; Osteocalcin; ERK; Osterix
INTRODUCTION
More than 40% of multiple myeloma (MM) patients experience skeletal complications that
jeopardize their quality of life and greatly increase the risk of death (1). Treatments
preventing bone disease may therefore result in prolonged survival. However, effective
therapies require the identification of the underlying pathogenic events. In MM, studies on
bone biopsies identified a dual mechanism of bone destruction, consisting of osteoclast (OC)
upregulation and inhibition of osteoblast (OB) activity (2).
OC activation in MM has been extensively studied and CCL3 is a critical player in this
context. CCL3, or MIP-1α in the old nomenclature, is a pro-inflammatory cytokine
belonging to the CC chemokine subfamily. CCL3 modulates OC differentiation by binding
to G-protein coupled receptors, CCR1 and CCR5, and activating ERK and AKT signaling
pathways. In the tumor niche, malignant plasma cells and OCs are the main sources for
CCL3 that promotes MM cell migration and survival, along with stimulation of
osteoclastogenesis (3, 4). Importantly, a clinical grade small molecule CCR1 antagonist,
MLN3897, inhibits CCL3-induced osteoclastogenesis and OC support of MM cells (5).
OB impairment is a frequent finding in MM, but the underlying mechanism has yet to be
fully clarified. OBs express CCL3 receptors and similar to other inflammatory cytokines,
such as TNF-α and TWEAK, CCL3 may also inhibit OB in MM (6-8). However, no studies
have addressed direct effects of CCL3 on osteoblastogenesis.
Here, we describe for the first time that CCL3 in addition to its known bone resorptive
effects, may reduce bone formation by inhibiting OB function. Our data suggests that CCL3
impairs matrix mineralization and suppresses osteocalcin (OCN) production. In particular,
CCL3 upregulates ERK activity and downregulates the osteogenic transcription factor
osterix. Importantly, CCR1 inhibition via MLN3897 blocks ERK phosphorylation and
restores, at least partially, OCN expression in vitro and in vivo. This data therefore suggests
that the pro-inflammatory chemokine CCL3 may contribute to OB/OC uncoupling
characteristic of MM bone disease, prompting the development of targeted strategies against
CCL3.
MATERIALS AND METHODS
Reagents
CCL3 (R&D Systems, Inc., Minneapolis, MN) was used at concentrations of 50 ng/ml
(unless otherwise specified), according to the manufacturer’s instructions. A neutralizing
antibody against CCL3 (R&D Systems, Inc, Minneapolis, MN) was used at concentrations
of 5 μg/ml. PD098059 (Sigma Aldrich, Saint Louis, MO), a specific inhibitor of the
activation of mitogen activated ERK kinase (MEK) 1/2, was reconstituted in ethanol and
stored at −20 C and used at a concentration of 30 μM. MLN3897, an orally active, small
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tmolecule specific antagonist of human CCR1, was kindly provided by Millennium
Pharmaceuticals (Cambridge, MA) (5). In vivo stable drug levels were obtained by means of
twice daily oral gavage with 2 mg/kg MLN3897 diluted in 0.5% methylcellulose and 0.2%
tween 80. The peak plasma concentrations reached by this schedule of administration
corresponded to 50 nM, subsequently used in the in vitro studies.
MM and BMSC cells
MM cell lines—Dexamethasone sensitive (MM.1S) and resistant (MM.1R) human MM
cell line was kindly provided by Dr Steven Rosen (Northwestern University, Chicago, IL)
(9). INA-6 human IL-6–dependent MM cell line was provided by Dr. Renate Burger (10)
(University of Kiel, Kiel, Germany) and cultured in the presence of 2.5 ng/mL IL-6 (R&D
Systems, Inc. Minneapolis, MN). RPMI cell line was obtained from the American Type
Culture Collection (ATCC, Rockville, MD). All MM cell lines were cultured in RPMI 1640
media (Sigma Chemical, Saint Louis, MO) containing 10% fetal bovine serum, 2 mM L-
glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin (Gibco, Grand Island, NY).
BMSC—We generated human BMSCs from MM patients by placing bone marrow
mononuclear cells in 75-mm2 culture flasks in RPMI 1640 media (Sigma Chemical, Saint
Louis, MO) containing 20% fetal bovine serum, 2 mM L-glutamine, 100 U/mL penicillin,
and 100 μg/mL streptomycin (Gibco, Grand Island, NY). Once confluent, the cells were
trypsinized and passaged as needed. Only cells between the second and the fourth passage
were used. We also used the BMSC cell line HS27A, obtained from the ATCC (Rockville,
MD) and cultured in 10% RPMI 1640 media.
OB differentiation
We cultured BMSC or HS27A cells (5000 cells/well) in the presence of osteoblastogenic
media as previously described (11).
Patient samples
We studied bone marrow (BM) plasma from 22 MM patients at diagnosis for CCL3 and
OCN expression by ELISA. All patients provided written informed consent per the
Declaration of Helsinki and approval was obtained by the institutional review board of the
Massachusetts General Hospital Cancer Center (Boston, MA).
ELISA
CCL3 and osteopontin (OPN) expression was analyzed by ELISA assays purchased from
R&D Systems (Minneapolis, MN) and OCN levels were assessed using the N-MID
osteocalcin ELISA kit (Immunodiagnostic Systems Inc, Fountain Hills, AZ). Supernatants
of MM cell lines and mature OBs, seeded in 10% FBS RPMI 1640 or 20% FBS α-MEM,
respectively, for 48 or 72 hours were assayed. All measurements were performed in
duplicates.
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For evaluation of surface receptor expression, cells were suspended in Dulbecco’s
phosphate-buffered saline and incubated for 30 minutes at 4°C with the primary antibody
anti-CCR1 and anti-CCR5 (phycoerythrin-conjugated, R&D Systems, Inc. Minneapolis,
MN). Data was acquired using the CellQuest software on a BD FACS Calibur (BD
Biosciences, California, USA) and analyzed with FlowJo software. Results are expressed as
fold change of mean fluorescence intensity compared to isotype control.
Real-time quantitative PCR
Gene expression was analyzed by quantitative-PCR on RNA extracted from OBs as
previously described. (11) Primers for ALPL (alkaline phosphatase), COL1A1 (collagen type
1 alpha 1), IBSP (bone sialoprotein), Bglap1 (osteocalcin), ATF4, RUNX2, SP7 (osterix)
were obtained from SuperArray (Frederick, MD). Transcript levels were normalized to β-
actin.
Immunofluorescence and immunohistochemistry
OCN protein expression was assessed by immunofluorescence (IF) and
immunohistochemistry (IHC) after incubating the samples overnight with 1:80 primary
antibody clone OC4-30 (Abcam, Cambridge, MA). IF was performed on OB differentiated
on culture slides (BD Biosciences San Jose, California) for 2 weeks in the presence or
absence of CCL3, media was changed twice weekly. Cells were then fixed, stained with
primary antibody and secondary anti-rabbit Alexa Fluor 488 conjugated antibody.
Counterstain was performed with DAPI. IHC was performed on paraffin-embedded sections
from human fetal bones. Antigen retrieval consisted of incubation with proteinase K
(ROCHE, Indianapolis, IN). After incubation with the primary antibody, slides were probed
with biotinylated secondary antibody (1:300) and signal detected with the Streptavidin-HRP
system provided by the TSA kit (Perkin Elmer-Life Sciences, MA, USA), according to the
manufacturer's guidelines. Immunostained areas were estimated by determining a threshold
on the basis of two positive control images and the threshold was used to analyze all the IHC
images (12). The values were then corrected per trabecular bone area.
Western blotting
HS-27A differentiated for 2 weeks with osteogenic media were stimulated with CCL3 in the
absence or presence of MLN3897 or PD098059 and lysed in lysis buffer as previously
described (5). Samples were then subjected to sodium dodecyl sulphate polyacrylamide gel
electrophoresis, transferred to PVDF membrane, and immunoblotted with antibodies against
pERK, ERK, pAKT, pP38, pβcatenin and βcatenin (Cell Signaling Technology, Beverly,
MA). Antigen-antibody complexes were detected by enhanced chemiluminescence
(Amersham, Arlington Heights, IL). The membrane was stripped and reprobed with anti-
actin antibody to ensure equal protein loading.
In vivo mouse model
All animal studies were conducted according to protocols approved by the Institutional
Animal Care and Use Committee of Dana Farber Cancer Institute (Boston, MA). The SCID-
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thu mouse model was generated as previously described (13). We treated 6 mice with oral
MLN3897 (2 mg/kg twice daily for 6 days/week) and 5 mice with vehicle for four weeks.
Tumor cell growth was monitored with weekly ELISA for soluble human IL6 Receptor
(sHuIL6R) (R&D Systems, Minneapolis, MN) in blood sera. At week 3 of treatment three
mice were sacrificed (2 in the treatment and 1 in the control group) because of increase in
fetal bone graft size. Since our primary endpoint was bone analysis, the remaining eight
mice were sacrificed at end of the treatment (week 4) and bone grafts harvested. After 72
hours fixation in 4% paraphormaldehyde, the bones were decalcified in 20% EDTA for 3
weeks and paraffin-embebbed. Cross-sections of each bone at different levels were
performed and all bones analyzed for bone area, tumor invasion, OC and OB number.
Trabecular bone area and tumor area as proportion of total tissue area were quantified on
H&E stained slides using a Nikon Eclipse 80i microscope and Image J analysis software
(14). OCs were identified after TRAP staining and hematoxylin counterstaining and
expressed as number per mm2 of trabecular bone. OBs were counted on H&E stained
sections as bone-lining cells, active OBs and osteocytes per mm2 of trabecular bone.
Statistical analysis
Each experiment was performed in quadruplicate and results have been expressed as mean ±
SD of at least three different experiments. Statistical comparisons of continuous variables
were performed by Student’s two-tailed t test. Association between OCN and CCL3 levels
in BM plasma from MM patients was assessed by Pearson correlation analysis.
RESULTS
MM-DERIVED PRIMARY OSTEOBLASTS AND HS27A STROMAL CELL LINE EXPRESS
CCL3 AND ITS RECEPTORS, CCR1 and CCR5
We first evaluated ligand and receptor expression levels in MM patient-derived OBs at
different stages of maturation. In vitro osteogenesis consists of three principal periods of
differentiation: i) mesenchymal stem cells proliferation during the first week of OB
differentiation, that we defined as immature OBs, ii) extracellular matrix maturation during
the second week of differentiation, that we defined as mature OBs, and iii) finally the third
week of mineralization (15). As shown in figure 1A, the average levels of CCL3 detected in
72h-culture supernatant of mature MM-derived OBs ranged between 1 and 231 pg/ml
(average 103.63 pg/ml). CCL3 production was 8 to 10 times lower compared to MM cell
lines (801.2 pg/ml ± 407.7) that represent the main source of CCL3 in the tumor niche (5,
16). To evaluate the potential effect of CCL3 on OB development and function, we assessed
the receptor expression levels both by RNA and protein levels. Mature OB express higher
levels of CCR1 and CCR5 mRNA compared to immature OB (2.5± 1.75 vs 1.52± 0.8 fold
increase, Figure S1). Similarly, assessment by flow cytometry suggested that osteogenic
differentiation upregulated both receptors with a 2.1 ± 0.81 and 1.7 ± 0.38 fold increase in
MFI, respectively, compared to isotype control at day 14 (Figure 1B) (7). We also
characterized the CCL3 pathway in a human stromal cell line, HS-27A that recapitulates the
features of primary human BMSC. HS-27A cells show preOB features (17, 18) and, in the
presence of osteogenic media, differentiate to ALP positive cells that mineralize in sheets
rather than nodules (Figure S2). CCL3 secretion was upregulated with OB differentiation
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tand, similar to patient-derived OBs, the average CCL3 production by mature HS27A-OB
was 112 ± 48 pg/ml (Figure 1C). We also observed that CCR1 and CCR5 expression in
HS27A cells is increased by osteogenic differentiation (1.82 ± 1.28 and 1.64± 0.96 fold
increase in MFI compared to isotype control, Figure 1D).
CCL3 INHIBITS OB MINERALIZATION ACTIVITY
The known upregulation of CCL3 in the MM niche (16) and the expression of the receptors
by OBs prompted us to evaluate its effects on OB development and activity. Using patient
derived cells we observed that CCL3 (50 ng/ml) did not affect alkaline phosphatase protein
(ALP) activity, a well established marker for OB differentiation (Figure 2A). On the
contrary, matrix mineralization was significantly impaired in OB cultures continuously
exposed to CCL3, as shown by a 50% decrease in calcium deposition compared to untreated
OBs (Figure 2B, p=0.01). This data suggests that CCL3 preferentially impairs OB function
rather than OB differentiation of MM-derived BMSC. Similarly, treating mature receptor-
positive HS27A-OB with increasing concentrations of CCL3 for one week inhibited
mineralization to basal control levels (Figure 2C), suggesting that late exposure to CCL3
inhibits mineralization and OCN expression as continuous treatment. As shown in figure
1A, MM cell lines produce high amounts of CCL3. To confirm the relevance of this
chemokine in MM-induced OB impairment, we exposed mature HS27A-OB to MM cell
culture supernatant in the presence or absence of neutralizing CCL3 antibodies. The
impaired mineralization observed in the presence of MM supernatant was reversed by
treatment with the neutralizing antibody against CCL3 (Figure 2D), suggesting that CCL3
may mediate MM inhibition of OB activity.
CCL3 DOWNREGULATES OSTEOCALCIN EXPRESSION VIA ERK AND OSTERIX
MODULATION
OB function is a complex process consisting mainly of matrix formation and mineralization,
and requiring the concerted expression of bone-specific proteins. OCN in particular is the
most abundant noncollagen protein in the bone matrix and stimulates bone mineral
maturation by stimulating the growth of apatite crystals (19, 20). CCL3 treatment
downregulated both RNA and protein levels of OCN by 40% and 23%, respectively (Figure
3A, p<0.05). In contrast, collagen type I alpha I, ALP, and bone sialoprotein gene
expression as well as osteopontin protein levels were not affected by exposure to CCL3
(Figure S3). CCL3 BM plasma levels are increased in MM patients with extensive bone
disease (21). Notably, we observed in patients with lytic lesions (n=14) a borderline
significant, negative correlation between BM plasma CCL3 and OCN expression (Figure S4,
r=−0.53; p=0.05).
CCL3/CCR interactions activate several downstream effectors, including the MAPK and
AKT signaling pathways (4). Western blot analysis of these effectors was used to determine
their contribution to CCL3 inhibitory effects on OB function. We observed early
upregulation of phospho-ERK in mature HS27A-OBs, associated with P38 and AKT
signaling activation at later time-points (Figure 3B). No changes in βcatenin and phospho-
βcatenin were observed (Figure S5A). Upon time and dose-dependent exposure to CCL3, we
noted increase in phospho-ERK expression as early as 30’ and starting from 10 ng/ml of
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tCCL3. Overall a 2-fold upregulation after 4 hour treatment with 50 ng/ml of CCL3 was
observed (p<0.01, Figure 3C). Importantly, undifferentiated HS27A did not show any ERK
pathway activation by CCL3 treatment, providing further evidence that CCL3 targets mainly
mature OB (Figure S5B). Downstream of ERK signaling pathway a cascade of transcription
factors critical to OB function have been identified. Gene expression analysis of osteoblastic
transcription factors in CCL3-treated HS27A-OBs revealed a time and dose-dependent
osterix downregulation, with a 2-fold decrease after 4 hours treatment with 50 ng/ml of
CCL3 (p=0.01, figure 3D). On the contrary, exposure to CCL3 did not significantly alter the
expression levels of RUNX2 or ATF4 (Figure 3E).
CCR1 INHIBITION AT LEAST PARTIALLY REVERSES CCL3 EFFECTS IN VITRO AND IN
VIVO
To provide additional evidence for the inhibitory effects of the CCL3/CCR1 pathway on OB
function, we blocked CCR1 using the small molecule human CCR1 antagonist, MLN3897,
previously studied for its anti-OC effects (5). Pretreatment of HS27A-OB with the CCR1
inhibitor at 50 nM suppressed CCL3-induced ERK activation (Figure 4A). In addition,
osterix transcription inhibited by CCL3 was at least partially restored by pretreatment with
the CCR1 inhibitor (Figure 4B). Similarly, pretreatment of HS27A-OB with the MEK1
inhibitor, PD098059 (Sigma Aldrich, St. Louis, MO) rescued osterix gene downregulation in
the presence of CCL3 (from 0.29 ± 0.27 to 1.72 ± 1.5 in PD098059 treated cells) (Figure
4C). Finally, OCN expression was increased by MLN3897 in the presence of CCL3 (from
0.39 ± 0.19 to 3.4 ±2.6 in the presence of MLN3897) (Figure 4D). This data suggests that by
modulation of the ERK signaling pathway CCL3 inhibits OB function via osterix inhibition
and downregulation of OCN expression. CCR1 is at least partially responsible for these
effects, although the role of other receptors such as CCR5 should not be excluded.
We then investigated the effects of CCR1 inhibition on tumor burden and bone structure in
an in-vivo setting using a humanized model of MM bone disease. 11 mice subcutaneously
implanted with fetal human bone chips and injected with INA6 MM cells, were treated with
MLN3897 or vehicle. Analysis of tumor burden during treatment by serial quantification of
sHuIL6R revealed delayed tumor growth in the treated group (Figure 5A, left panel). No
weight loss or other toxicities were observed. Importantly, the tumor infiltration of the bone
specimens decreased from 40.6% in the control to 26% in the treated mice confirming a
reduction in MM burden (Figure 5A, right panel). Treatment with the CCR1 inhibitor
induced a 2-fold increase in trabecular bone area per tissue area (15.9 ±5.59 vs 27±14.9)
(Figure 5B) and a 1.5 fold decrease in OC number per trabecular bone area compared to the
control group (46.2 ±26/mm2 vs 29±12/mm2) (Figure 5C), confirming our previous in vitro
findings on the important role of CCR1 in osteoclastogenesis (5). We then evaluated the
effects of CCR1 inhibition on the OB compartment of the tumor milieu by assessing OB
number and activity via detection of OCN in the trabecular bone. No differences in the
number of OB per trabecular bone area were observed (575± 94.4/mm2 in the control group
vs 506± 62.1/mm2 in the treated group) (Figure 5D, left panel). However, the ratio of the
OCN positive areas per trabecular bone area was increased in the MLN3897 treated animals
(0.26 ±0.28 vs 0.53±0.34) (Figure 5D, middle and right panel). These results suggest that
CCR1 inhibition may impact OB activity indirectly via OC inhibition. Furthermore, based
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signaling. Future studies will confirm these effects with larger sample size.
DISCUSSION
Understanding the cellular interactions within the tumor-bone milieu is critical to the
development of novel agents simultaneously targeting myeloma cells and reversing bone
disease. The proinflammatory chemokine CCL3 plays a critical role in tumor development
and disruption of bone homeostasis via OC stimulation. Here, we demonstrate for the first
time that CCL3 may contribute to the OB/OC uncoupling not only by promoting OC activity
but also by inhibiting OB activity. We investigated the CCR/CCL3 pathway in OBs and
observed that exogenous and tumor-derived CCL3 inhibits OB mineralization and OCN
expression. Our data shows that modulation of ERK signaling and osterix expression
mediate CCL3 effects, and CCR1 inhibition may reverse at least partially these effects.
Both receptors for CCL3 have been identified on BMSC and OB surface, although
expression levels vary according to cell type and species (7, 22, 23). Here, we observed
upregulation of both CCR1 and CCR5 during osteogenesis from primary cells and the
human stromal cell line, HS27A. The receptor expression observed on mature cells may
account for the preferential inhibition of OB function rather than differentiation; explaining
also the different effects on ALP, an early OB gene, and OCN, produced typically by mature
cells. Notably, specific CCR1 inhibition only partially reverses CCL3 effects, while
neutralizing antibody against CCL3 completely restores OB activity, suggesting that CCR5
may also play a key role in mediating CCL3 effects on OBs. Targeted receptor inhibition
will be used to address this question in future studies.
Inhibition of OB is a frequent finding in bone biopsies of MM patients and correlates with
tumor burden (2). MM cells block OB differentiation by means of contact-mediated RUNX2
inhibition (24), tumor cell secretion of β-catenin antagonists such as DKK1 (25) and tumor
induced production of OB inhibitors by BMSC, such as activin A (11). As observed with
other inflammatory cytokines such as TWEAK and TNFα, here we observed that tumor-
derived CCL3 downregulates OB mineralization activity, at least partially, via OCN
inhibition (8, 26).
Myeloma patients with extensive bone disease have high serum levels of CCL3 (21). In
addition, high expression levels of the cytokine have been identified on tumor plasma cells
(27), correlating with extent of osteolysis. Interestingly, we observed a negative correlation
between CCL3 and OCN levels in patients with high osteolytic burden. Although increased
tumor burden and OC activity decreased OCN levels via OB inhibition, this data may also
reflect a direct negative regulation of OCN by CCL3. Therefore, CCL3 contribution to
development of osteolytic lesions relies on a dual effect on OC and OB. In addition, our in
vitro and in vivo data suggests that CCL3 pathway inhibition restores OB function and
therefore targeted therapies against CCL3 may be of benefit by reversing the OB/OC
uncoupling typical of MM.
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tThe MAPK signaling pathway represents an important modulator of OB differentiation: the
concerted activation and inhibition of ERK, p38 and JNK regulate the expression of several
osteogenic transcription factors (28). In particular, the ERK pathway exerts opposite effects
on OBs according to the differentiation stage. Continuous inhibition of ERK signaling
promotes OB development, whereas activation during late stages of differentiation inhibits
osteogenesis. (28-31). Our data suggests that exposing differentiated OBs to CCL3 activates
ERK signaling, which in turn downregulates osterix expression, as previously observed with
TNF-α (26). Interestingly, one of the mechanisms of OB inhibition by proinflammmatory
cytokines is sclerostin upregulation (8), whose role in mediating CCL3 effects on OBs will
be assessed in future studies. CCL3 has been mainly considered as a pro-osteoclastogenic
cytokine promoting catabolic activity in the pathogenesis of bone disease. Our results
identify a novel effect of CCL3, as an inhibitor of OB function and a mediator of OB/OC
uncoupling in MM. Therefore, we provide further evidence for the important pathogenic
role played by CCL3 and its receptors in MM and for the need to assess targeted inhibitors
of this pathway in upcoming clinical trials.
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tFigure 1. Differentiated osteoblasts secrete CCL3 and express its receptors
(A) ELISA detection of CCL3 in 72h-culture supernatant from several myeloma (MM) cell
lines and patient-derived osteoblasts (OB). (B) (upper panel) Fold increase of CCR1 and
CCR5 surface expression during OB differentiation assessed by flow cytometry. (Lower
panel) Representative flow cytometric analysis of receptor expression on OB at day 7 and
day 14 of differentiation compared to isotype control. (C) CCL3 expression levels from
culture supernatant of HS-27A cells during OB differentiation and (D) CCR1 and CCR5
surface expression detected by flow cytometry.
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tFigure 2. CCL3 inhibits OB mineralization
(A) The ratio of alkaline phosphatase activity relative to the amount of viable cells (API) in
2-week differentiated OBs with or without CCL3 50 ng/ml. (B) (upper panel)
Representative image of alizarin red staining to detect mineralization from OB exposed to
CCL3 for 3 weeks. (Lower panel) Quantification of calcium deposition in OB differentiated
with or without CCL3 50 ng/ml for 3 weeks. (C) Alizarin Red assessment of HS27A-
derived mature OB treated for one week with CCL3 from 10 to 100 ng/ml. (D)
Quantification of mineralization via alizarin red in HS27A-derived mature OB exposed to
INA6 and MM.1S cell supernatant for one week with or without neutralizing antibody
against CCL3 (*, p < 0.05).
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tFigure 3. CCL3 downregulates osteocalcin expression via ERK and osterix modulation
(A) Osteocalcin (OCN) expression in mature MM-derived OBs, with or without CCL3 (50
ng/ml), detected via (left panel) quantitative PCR analysis, (middle panel) ELISA on
culture supernatant, and (right panel) immunofluorescent detection of OB cultures (OCN is
stained with Alexa Fluo 488, counterstain with DAPI). (B) Western blot detection of pERK,
pAKT, pP38, ERK1/2 on HS27A-derived OB exposed to CCL3 50 ng/ml for the specified
time points. (C) Western blot detection of pERK and ERK1/2 in HS27A-derived OB after
dose-dependent exposure to CCL3. A densitometric analysis averaging more than 3
experiments is shown. (D) Osterix gene expression assessed by quantitative PCR in OB
exposed to increasing time and doses of CCL3. (E) RUNX2 and ATF4 gene expression
evaluation on mature OBs in the presence of CCL3 (4h, 50 ng/ml) (* p<0.05, ** p<0.01)
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tFigure 4. CCR1 mediates at least partially CCL3 inhibitory effects on OBs
(A) Western blot detection of pERK and ERK signaling in HS27A-derived OB treated with
CCL3 in the presence of a small molecule CCR1 inhibitor (50 nM). (B) Osterix gene
expression by quantitative PCR in OB treated for 4 hours with CCL3 with or without the
CCR1 inhibitor (50 nM) (left panel) or MEK1 ihibitor, PD098059 (30 μM, 1h pretreatment)
(right panel). (C) Osteocalcin gene expression by quantitative PCR in OB treated for 24
hours with CCL3 with or without the CCR1 inhibitor (50 nM) (* p<0.05).
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tFigure 5. In vivo CCR1 inhibition in a MM mouse model
(A) (Left panel) Weekly assessment of tumor burden via soluble human IL6 receptor
(shuIL6R) levels during treatment. Values are expressed as fold increase. (Right panel)
Tumor invasion was also assessed and expressed as % of tissue area (B) (Left panel)
Representative image of H&E staining on MM-injected bone chips from control and treated
mice. (Right panel) Bone area was counted and represented as % of total tissue area. (C)
(Left panel) Representative image of immunocytochemistry for TRAP activity on MM-
injected bone chips from control and treated mice. (Right panel) The number of TRAP+
cells per bone area was counted. (D) (Left panel) OB number per bone area was assessed on
both control and treated bones. (Middle panel) Representative image of
immunohistochemical detection of OCN on the MM-injected bone chips. (Right panel) The
percentage of OCN positive area per bone area was analyzed.
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